ClinicalTrials.gg
Not yet recruitingNCT06516055Updated Apr 27, 2025

Study of S1B-408 in Women With Orgasmic Dysfunction

A Phase 2 interventional study of S1B-408 in Orgasmic Disorder, sponsored by S1 Biopharma, Inc.. Not yet recruiting. Open to female participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by S1 Biopharma, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
25 Years to 60 Years
Sex
Female
01

Study summary

This is the first clinical trial of S1B-408 in women with sexual dysfunction. A prior 4-week trial in premenopausal women with Hypoactive Sexual Desire Disorder showed that orgasmic function improved with Lorexys (TM). This pilot trial tests for improvement in orgasmic function, safety, and tolerability of a different but related test article.

Read the detailed description

S1B-408 is a proprietary combination of agents proven safe and effective in other CNS indications. The combination drug is aimed at treating women's sexual dysfunction disorders. Its two components each have pro-sexual effects. However, the efficacy of each when given alone has been limited. Moreover, each component has side effects which, while benign, may limit the drug's utility: activation (agitation, anxiety, insomnia) with one; sedation (somnolence, fatigue, etc) with the other.

The goal of this trial is to show that, when formulated in the proper (fixed) ratio, the combination of these two drugs strengthens their pro-sexual effects for orgasmic dysfunction while mitigating the opposing side effect profiles.

For this pilot study, the goal for exposure is to seek rapid onset of action with minimal dosing.

02

Conditions studied

  • Orgasmic Disorder

Keywords

  • S1B-408
  • Orgasmic Disorder
  • Female Sexual Dysfunction
03

In context

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 114 interventional studies indexed under Sexual Dysfunctions, Psychological.

Browse Sexual Dysfunctions, Psychological studies →

Lead sponsor

S1 Biopharma, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 25 to 60.
  2. In a sexual relationship and sexually active within the past month
  3. Diagnosis of ICD-10 2023 Orgasmic Dysfunction, secondary or primary. See Investigator's Brochure, section 2, "Medical Need and Diagnosis" for rationale.
  4. Orgasmic Dysfunction is the predominant form of sexual dysfunction, is acquired rather than lifelong, and is generalized rather than situational.
  5. At screen and baseline visit, scores \<8 on the raw score of the FSFI orgasm domain (at least moderate severity)
  6. May have depression and/or anxiety if condition is no worse than mild with treatment and if patient will continue the same treatment for the duration of this trial
  7. Side effects from any continuing concomitant medications must be stable.
  8. Not pregnant or lactating for six months; using that is medically reliable in the investigator's judgment, or (if the investigator finds the patient credibly monogamous) vasectomy of male partner. If hormonal contraception is used, the same medication must have been used for at least 3 months.
  9. Gives for and is willing to undergo all of the scheduled evaluations
  10. Prompt for screening and baseline visits, is cooperative, and takes reasonable directions without excessive explanations
  11. Her sexual partner is sexually unimpaired (erectile dysfunction allowed only if adequately treated), and available to the subject at least half of the time (in days per week).
  12. Agrees to have sexual activity with her partner at least once a week for the duration of her participation in this study.

Exclusion criteria

Exclusion Criteria:

  1. Masturbates to orgasm more than once a week.
  2. Sexual aversion or sexual pain disorder
  3. Chronic conditions that, in the investigator's judgment, are likely to deteriorate within 3 months of screening are not allowed (e.g., gastrointestinal bleeding, uncontrolled diabetes, frequent asthma attacks, uncontrolled Major Depressive disorder, history within the prior 6 months of suicidality or drug abuse; recurrence within the prior year of breast, cervical, uterine, ovarian or other systemic cancer). However, chronic conditions with a relatively stable course are allowed; see Investigator's Brochure, section 2, "Medical Need and Diagnosis" for rationale.
  4. Requires , CYP 2B6, or CYP 2D6 strong inhibitor or inducer drugs
  5. History of bipolar and/or psychotic disorders and/or takes an antiepileptic/mood stabilizer, antipsychotic, or opioid drug
  6. History of severe, serious, or allergic adverse reaction(s) to stimulants or sedatives
  7. Drinks >2 alcoholic drinks per day (12-oz beer, 4-oz wine, 1 ½ oz liquor, etc.)
  8. History of seizures or use of antiepileptic medication
  9. Long syndrome (QTc >480 msec), other significant cardiovascular disease
  10. moderate or severe dysfunction of the liver (any LFT >3x ) or renal dysfunction (BUN > 30 or Cr >2.0)
  11. History of blood clots or abnormal bleeding tendencies, including daily use of medications adversely affecting coagulation, e.g., NSAIDs, systemic , or >81 mg aspirin daily.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    S1B-408

    One dose of S1B-408 with up-titration of one of its components after one week as needed and tolerated

    Drug: S1B-408

Interventions

  • DrugS1B-408

    Medication with multiple monoamine activities

06

What researchers measure

Primary outcomes

  1. Female Sexual Function Index (FSFI): orgasm domain

    sum of 3 items on orgasmic frequency, difficulty, and satisfaction, each rated 0 or 1 (worst) to 5 (best)

    Time frame: 7 or 28 day recall

Secondary outcomes

  1. Changes in Sexual Function Questionnaire (CSFQ): orgasm

    sum of 3 items on orgasmic frequency, pleasure, and ability, each rated 1 (worst) to 5 (best)

    Time frame: 7 day recall

  2. CSFQ total score

    sum of 14 items on all aspects of female sexual response, scored from 14 to 70 (best)

    Time frame: "now" or 7 day recall

  3. FSFI total score

    sum of 19 items on 6 aspects of female sexual response, scored from 4 (worst) to 95 (best)

    Time frame: Prior 7 or 28 days

  4. Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) items 13, 14, and 15 scores

    3 items on sexual distress re desire, arousal, and orgasm, each scored from 0 to 4 (best)

    Time frame: Prior 7 or 28 days

  5. Sexual Activity Log (SAL), orgasms

    Sexual Activity Log count of orgasms

    Time frame: 1-7 day recall

  6. SAL proportion of sexual activities with orgasm

    Sexual Activity Log count of orgasms over times engaged in sex; best would be 1.0

    Time frame: 1-7 day recall

  7. Sexual Activity Log (SAL) satisfying sexual events

    Count of sexual events that were satisfying

    Time frame: 1-7 day recall

  8. Patient's Global Impression of Change

    single question rated from 1 (best) to 7 (worst) asking improvement vs none or worsening

    Time frame: 4 weeks

Other outcomes

  1. Safety: adverse events

    All adverse outcomes in clinician's judgment in answer to a question: How do you feel? or in interpreting objective information about the patient

    Time frame: 4-week recall

  2. pulse rate

    number of heart beats per minute effective enough to reach the arm

    Time frame: one fourth to one half minute

  3. Blood pressure

    pressures in mm of mercury when a heartbeat reaches the arm and between heartbeats

    Time frame: one half minute or less

  4. Q-T interval

    time in milliseconds between start and end of a contraction of the ventricles of the heart as measured by electrocardiogram (ECG)

    Time frame: three heartbeats up to the number of heartbeats in 30 seconds

  5. Cardiac rate

    Number of contractions of the ventricles of the heart per minute as measured by ECG

    Time frame: 1/2 to 1 minute

  6. Columbia Suicide Severity Rating Scale, 6-item Screening/Triage version (C-SSRS-6)

    6-item self-rating scale on suicidal ideas, intent and behavior monitored by clinician; "no" rather than "yes" answer to each item is best score

    Time frame: prior 30 days

  7. Patient Health Questionnaire-9 Symptom Checklist (PHQ-9)

    9 items on depressive symptoms rated from 0 (best) to 3 (worst)

    Time frame: prior 2 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Pyke RE, Clayton AH. Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women. J Sex Med. 2019 Dec;16(12):1885-1894. doi: 10.1016/j.jsxm.2019.09.005. Epub 2019 Oct 31. PubMed 31678098 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Dec 2026, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 23, 2024
StartEst.
Jul 1, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Mar 30, 2027
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06516055
Lead sponsor
S1 Biopharma, Inc.
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Jul 1, 2025 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Apr 27, 2025

Study contacts

Anita Clayton, MD
Contact
AHC8V@hscmail.mcc.virginia
4342434649
Robert E Pyke, MD,PhD
Contact
robertepyke@gmail.com
2033992390
Nicolas E Sitchon, B.S.
study chair · S1 Biopharma, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion